Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
histone deacetylase inhibitor |
| gptkbp:administeredBy |
oral route
|
| gptkbp:ATCCode |
none (not assigned)
|
| gptkbp:CASNumber |
209783-80-2
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
Syndax Pharmaceuticals
|
| gptkbp:hasInChIKey |
QJQYQKZDHGQXQJ-SECBINFHSA-N
|
| gptkbp:hasMolecularFormula |
C15H14N2O2
|
| gptkbp:hasSMILES |
CCN1C=C(C2=CC=CC=C21)C=CC(=O)NO
|
| gptkbp:hasUNII |
8QJ6Q6K8HF
|
| https://www.w3.org/2000/01/rdf-schema#label |
entinostat
|
| gptkbp:investigated_for_treatment_of |
gptkb:non-small_cell_lung_cancer
gptkb:cancer hematological malignancies |
| gptkbp:is_investigational_drug |
true
|
| gptkbp:IUPACName |
(S)-3-(1-ethyl-1H-indol-3-yl)-N-hydroxy-2-propenamide
|
| gptkbp:mechanismOfAction |
inhibits class I histone deacetylases
|
| gptkbp:molecularWeight |
254.28 g/mol
|
| gptkbp:PubChem_CID |
CHEMBL1201832
DB12020 11364422 |
| gptkbp:synonym |
MS-275
SNDX-275 |
| gptkbp:target |
gptkb:HDAC3
gptkb:HDAC9 gptkb:HDAC1 |
| gptkbp:bfsParent |
gptkb:Histone_deacetylase
|
| gptkbp:bfsLayer |
7
|